文献速递白血病

慢性期慢性髓性白血病的治疗进展

How I treat chronic-phase chronic myelogenous leukemia.
PubMed 文献 · Blood · 2022-01-01

本文以病例形式综述慢性期慢性髓性白血病(CML)临床治疗的新进展。自2001年伊马替尼获批及后续达沙替尼、尼洛替尼、博舒替尼、普纳替尼相继问世后,疾病分子负荷显著下降,进展为加速期或急变期的患者大幅减少。文章讨论了博舒替尼与在研药物阿西米尼、普纳替尼的心脏安全性数据与个体化给药,以及女性生育规划和达到特定里程碑后停药。

要点

  • 多款TKI使CML分子负荷更深更快下降,进展期患者显著减少。
  • 博舒替尼的审批历程凸显何为TKI最佳应答的问题。
  • 普纳替尼需关注心脏安全性并依据个体应答调整给药。

核心结论

  • 多款TKI问世后CML治疗显著改善,分子负荷下降更深更快,进展为加速期或急变期者大幅减少,治疗可个体化并涵盖生育规划与停药。

研究设计与样本

  • 本文为综述性文章,通过展示示例病例回顾CML临床治疗的新近方面,未报告系统检索范围。

主要发现

  • 第一代TKI伊马替尼即显著降低分子疾病负荷,加用达沙替尼(2006)、尼洛替尼(2007)、博舒替尼(2012)、普纳替尼(2013)后下降更深更迅速。
  • 对一线治疗无应答或不耐受的患者有了更多选择,进展为加速期或急变期的患者数量大幅减少。
  • 博舒替尼在美国FDA的审批历程凸显了何为TKI最佳应答的问题。
  • 阿西米尼目前仍在临床试验中,文中将介绍其更新信息。
  • 普纳替尼存在理解心脏安全性数据的挑战,并采用基于个体应答的独特给药方案。

关键数值与推荐

  • 文中涉及的具体应答标准与数值原文未报告。

临床怎么用

  • 可根据患者个体情况选择与调整TKI治疗,一线无应答或不耐受者有替代选择。
  • 应用普纳替尼时需理解其心脏安全性数据并依据个体应答调整给药方案。
  • 对女性CML患者应纳入生育规划讨论,达到特定治疗里程碑后可考虑停药。

局限性

  • 本文为病例式综述,未提供系统检索策略及具体疗效数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

When imatinib, the first tyrosine kinase inhibitor (TKI) developed for use in chronic myelogenous leukemia (CML), was approved in 2001, the treatment of this disease was forever changed. Significant reductions in the molecular burden of disease were seen with the first-generation TKI imatinib and, with the addition of dasatinib (2006), nilotinib (2007), bosutinib (2012), and ponatinib (2013), deeper and more rapid reductions were noted. Physicians could begin to tailor TKI therapy to individual patients, and patients who did not respond to or could not tolerate first-line therapy now had options. Importantly, the number of patients who developed accelerated or blast phase disease decreased dramatically. Research in CML continues to evolve; by presenting illustrative cases, this article reviews some of the newer aspects of clinical care in this disease. Updated information regarding bosutinib and asciminib, the latter currently in clinical trials, will be presented; bosutinib is of particular interest as the drug's transit through the United States Food and Drug Administration highlights the question of what is considered optimal response to TKI therapy. The challenge of understanding the cardiac safety data of ponatinib and the unique dosing schedule based on individual response will be discussed. Lastly, two cases will focus on features of TKI treatment that, remarkably, have become part of the treatment algorithm: family planning for women with CML and stopping therapy after meeting a specific treatment milestone.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Berman E. How I treat chronic-phase chronic myelogenous leukemia. Blood. 2022. PMID: 34529784. doi:10.1182/blood.2021011722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。